[Ip-health] JLME special issue on pharm innovation and law

[Aidan Hollis]

The Journal of Law, Medicine & Ethics has special issue on
pharmaceutical innovation and law. There are several articles
discussing, among other things, compulsory licensing.

The table of contents is partially copied below.

The article by Sean Flynn, Mike Palmedo and me offers an explanation
of why drug companies so often don't engage in substantial price
discrimination across countries, and shows that in the conditions that
typically arise in poor countries, the profit maximizing price may be
extremely high, leading to low sales volumes (with low profits) for
innovator companies, and hence little incentive to invest in R&D,
while causing enormous losses in welfare to patients unable to afford
important medicines.

Aidan Hollis
Professor of Economics

University of Calgary, 2500 University Dr NW Calgary AB T2N 1N4 Canada
tel: +1 403 220 5861  fax: +1 403 220 5861
email: ahollis@ucalgary.ca
web: http://econ.ucalgary.ca/hollis.htm

Incentives for Global Health
http://www.healthimpactfund.org


Symposium Articles
INTRODUCTION: Pharmaceutical Innovation: Law & the Public's Health (p
173-175)
Kevin Outterson

I. PATENTS, INNOVATION & PUBLIC HEALTH
Using Patent Data to Assess the Value of Pharmaceutical Innovation (p
176-183)
Aaron S. Kesselheim, Jerry Avorn

An Economic Justification for Open Access to Essential Medicine
Patents in Developing Countries (p 184-208)
Sean Flynn, Aidan Hollis, Mike Palmedo


Developing Nations and the Compulsory License: Maximizing Access to
Essential Medicines While Minimizing Investment Side Effects (p 209-221)
Robert C. Bird


Compulsory Licensing in Canada and Thailand: Comparing Regimes to
Ensure Legitimate Use of the WTO Rules (p 222-239)
Kristina M. Lybecker, Elisabeth Fowler


Wild-Card Patent Extensions as a Means to Incentivize Research and
Development of Antibiotics (p 240-246)
Jorn Sonderholm


II. INVITED REVIEWS

Comment: Compulsory Licensing of Patented Pharmaceutical Inventions:
Evaluating the Options (p 247-263)
Jerome H. Reichman


Commentary: Innovation Policy for a New Era (p 264-268)
Amy Kapczynski